Evidence map›Paper›PMID 40016836›Full record

ArticleBMC pharmacology & toxicology2025

Development and validation of a nomogram to predict linezolid-induced thrombocytopenia in hospitalized adults.

Ya Yang, Xiaogang Hu, Ya Ran, Hongqian Wang, Peishu Fu, Pengpeng Wan, Zhongqing Deng, Xiaoqin Lang, Ning Wang, Fengjun Sun and 2 more

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ya Yang *Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Department of Pharmacy, National Clinical Research Center for Child Health and Disorders, Children's Hospital of Chongqing Medical University, No. 20 Jinyu Avenue, Liangjiang New District, Chongqing, 401122, China.
Xiaogang Hu *Department of Pharmacy, Chongqing Jiulongpo People's Hospital, Chongqing, 400051, China.
Ya RanDepartment of Pharmacy, Armed Police Hospital of Chongqing, Chongqing, 400015, China.
Hongqian WangMedical Big Data and Artificial Intelligence Center, The First Affiliated Hospital of Army Medical University, Chongqing, 400038, China.
Peishu FuDepartment of Pharmacy, The First Affiliated Hospital of Army Medical University, Chongqing, 400038, China.
Pengpeng WanDepartment of pharmacy, Dejiang Nation Hospital of TCM, Guizhou, 565299, China.
Zhongqing DengDepartment of pharmacy, Jiangjin District Central Hospital of Chongqing, Chongqing, 402260, China.
Xiaoqin LangDepartment of Pharmacy, The First Affiliated Hospital of Army Medical University, Chongqing, 400038, China.
Ning WangDepartment of Pharmacy, The First Affiliated Hospital of Army Medical University, Chongqing, 400038, China.
Fengjun SunDepartment of Pharmacy, The First Affiliated Hospital of Army Medical University, Chongqing, 400038, China.
Yahan FanDepartment of Blood Transfusion, The First Affiliated Hospital of Army Medical University, No. 30 Gaotanyan Street, Shapingba District, Chongqing, 400038, China. fyh@tmmu.edu.cn.
Yuntao JiaMinistry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Department of Pharmacy, National Clinical Research Center for Child Health and Disorders, Children's Hospital of Chongqing Medical University, No. 20 Jinyu Avenue, Liangjiang New District, Chongqing, 401122, China. jiayuntaomail@hospital.cqmu.edu.cn.

Funding

Future Medicine Youth Innovation Team Project of Chongqing Medical University W0081General Project of Chongqing Science and Health Joint Medical Scientific Research Project 2024MSXM177Key Project of Chongqing Science and Health Joint Medical Scientific Research Project 2022ZDXM020
6 · The paper itself

Abstract

backgroundLinezolid (LZD) is used to treat infectious diseases caused by Gram-positive bacteria, but thrombocytopenia is one of the main adverse reactions to LZD administration. Early prediction of linezolid-induced thrombocytopenia (LI-TP) is of great importance to improve the clinical outcomes and prognoses. The aim of this study was to develop and validate a prediction model for LI-TP.

methodsA retrospective cohort of hospitalized adults receiving LZD therapy (January 2014-June 2022) was analyzed. Independent risk factors for LI-TP were identified via logistic regression in the training set (n = 757). A nomogram model for LI-TP were developed based on independent risk factors, and verified in validation set (n = 123).

resultsThe incidence of LI-TP was 13.5% (102/757). A logistic regression model was developed based on the seven independent risk factors, including age (≥ 60 y), duration of LZD therapy (> 11 d), bPLT (< 308 × 10

conclusionThis nomogram provides a practical tool for stratifying LI-TP risk, which provide an important reference for enabling timely clinical interventions to enhance LZD safety.

Indexed as

Anti-Bacterial AgentsLinezolidNomogramsThrombocytopeniaAdultAgedAged, 80 and overFemaleHospitalizationHumansMaleMiddle AgedRetrospective StudiesRisk FactorsAnti-Bacterial AgentsLinezolidAdverse reactionLinezolidPrediction modelRisk factorsThrombocytopenia

Identifiers

PMID40016836
PMCPMC11869706

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.